ROl Data Summary
The MADCaP R01 cohort currently includes 1,233 participants across nine research centers in five countries: Nigeria, Ghana, Senegal, South Africa, and Uganda. This tissue-based study collects prostate tissue samples alongside clinical information to better understand prostate cancer characteristics and outcomes across African populations. Clinical data indicate a substantial burden of advanced prostate cancer, with 75% of participants having PSA levels above 20 ng/mL, 46% having biopsy Gleason scores of 8–10, and 55% of those with known metastatic status presenting with distant metastases.
Follow-up data is currently available for approximately half of the cohort (622 participants). Among participants with known vital status, 56% of which were attributed to prostate cancer. Median follow-up was 19.1 months.
Overall, these findings highlight the substantial clinical burden of prostate cancer in the R01 cohort. The tissue and clinical data provide an opportunity to better understand prostate cancer across diverse African populations, although incomplete follow-up remains a limitation when evaluating long-term outcomes.
U01 Data Summary
The MADCaP U01 cohort consists of 5,368 prostate cancer cases across nine research sites in four African countries: South Africa, Ghana, Nigeria, and Senegal. Of these, 2,829 were prostate cancer cases and 2,534 were controls. South Africa contributed the largest proportion of participants (46.1%), followed by Ghana (25.9%), Nigeria (14.4%), and Senegal (9.8%).
The majority of participants were aged between 60 and 74 years, with the largest age group being 65–69. 35.1% had PSA levels of 100 or higher, while 30.9% had levels between 20 and 99.9. Biopsy Gleason scores varied, with 3+4 being the most common (24.3%), followed by 4+3 (18.9%) and 3+3 (17.7%).
